159 related articles for article (PubMed ID: 25406200)
1. Tumour-associated osteomalacia and hypoglycaemia in a patient with prostate cancer: is Klotho involved?
Latifyan SB; Vanhaeverbeek M; Klastersky J
BMJ Case Rep; 2014 Nov; 2014():. PubMed ID: 25406200
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1.
Hannan FM; Athanasou NA; Teh J; Gibbons CL; Shine B; Thakker RV
Eur J Endocrinol; 2008 Feb; 158(2):265-71. PubMed ID: 18230836
[TBL] [Abstract][Full Text] [Related]
3. Tumour-induced osteomalacia.
Minisola S; Peacock M; Fukumoto S; Cipriani C; Pepe J; Tella SH; Collins MT
Nat Rev Dis Primers; 2017 Jul; 3():17044. PubMed ID: 28703220
[TBL] [Abstract][Full Text] [Related]
4. Tumour-induced osteomalacia: a literature review and a case report.
Dadoniene J; Miglinas M; Miltiniene D; Vajauskas D; Seinin D; Butenas P; Kacergius T
World J Surg Oncol; 2016 Jan; 14(1):4. PubMed ID: 26744291
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.
Imel EA; Peacock M; Pitukcheewanont P; Heller HJ; Ward LM; Shulman D; Kassem M; Rackoff P; Zimering M; Dalkin A; Drobny E; Colussi G; Shaker JL; Hoogendoorn EH; Hui SL; Econs MJ
J Clin Endocrinol Metab; 2006 Jun; 91(6):2055-61. PubMed ID: 16551733
[TBL] [Abstract][Full Text] [Related]
6. Metastatic prostate cancer presenting as tumour-induced osteomalacia.
Layman AAK; Joshi S; Shah S
BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31315844
[TBL] [Abstract][Full Text] [Related]
7. FGF23: mediator of poor prognosis in a sizeable subgroup of patients with castration-resistant prostate cancer presenting with severe hypophosphatemia?
Lee EK; Martinez MC; Blakely K; Santos KD; Hoang VC; Chow A; Emmenegger U
Med Hypotheses; 2014 Oct; 83(4):482-7. PubMed ID: 25155552
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic osteomalacia: two case reports with surprisingly different outcomes.
Seijas R; Ares O; Sierra J; Pérez-Dominguez M
Arch Orthop Trauma Surg; 2009 Apr; 129(4):533-9. PubMed ID: 19125258
[TBL] [Abstract][Full Text] [Related]
9. Tumor-induced osteomalacia associated with a maxillofacial tumor producing fibroblast growth factor 23: report of a case and review of the literature.
Mori Y; Ogasawara T; Motoi T; Shimizu Y; Chikazu D; Tamura K; Fukumoto S; Takato T
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Mar; 109(3):e57-63. PubMed ID: 20219587
[TBL] [Abstract][Full Text] [Related]
10. Elevated fibroblast growth factor 23 in a patient with metastatic prostate cancer and hypophosphatemia.
Cotant CL; Rao PS
Am J Kidney Dis; 2007 Dec; 50(6):1033-6. PubMed ID: 18037105
[No Abstract] [Full Text] [Related]
11. Hypophosphatemia related to paraneoplastic Cushing syndrome in prostate cancer: cure after bilateral adrenalectomy.
Ramon I; Kleynen P; Valsamis J; Body JJ; Karmali R
Calcif Tissue Int; 2011 Dec; 89(6):442-5. PubMed ID: 21910004
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma.
Leaf DE; Pereira RC; Bazari H; Jüppner H
J Clin Endocrinol Metab; 2013 Mar; 98(3):887-91. PubMed ID: 23393166
[TBL] [Abstract][Full Text] [Related]
13. Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition.
Mak MP; da Costa e Silva VT; Martin RM; Lerario AM; Yu L; Hoff PM; de Castro G
Support Care Cancer; 2012 Sep; 20(9):2195-7. PubMed ID: 22552356
[TBL] [Abstract][Full Text] [Related]
14. Hypophosphataemia due to FGF-23 producing B cell non-Hodgkin's lymphoma.
Elderman JH; Wabbijn M; de Jongh F
BMJ Case Rep; 2016 Apr; 2016():. PubMed ID: 27118742
[TBL] [Abstract][Full Text] [Related]
15. FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism.
Fukumoto S
Calcif Tissue Int; 2016 Apr; 98(4):334-40. PubMed ID: 26126937
[TBL] [Abstract][Full Text] [Related]
16. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T
Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126
[TBL] [Abstract][Full Text] [Related]
17. Locally aggressive and multifocal phosphaturic mesenchymal tumors: two unusual cases of tumor-induced osteomalacia.
Higley M; Beckett B; Schmahmann S; Dacey E; Foss E
Skeletal Radiol; 2015 Dec; 44(12):1825-31. PubMed ID: 26341245
[TBL] [Abstract][Full Text] [Related]
18. Tumour-induced osteomalacia: An emergent paraneoplastic syndrome.
Alonso G; Varsavsky M
Endocrinol Nutr; 2016 Apr; 63(4):181-6. PubMed ID: 26718193
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia.
Ito N; Shimizu Y; Suzuki H; Saito T; Okamoto T; Hori M; Akahane M; Fukumoto S; Fujita T
J Intern Med; 2010 Oct; 268(4):390-4. PubMed ID: 20698924
[No Abstract] [Full Text] [Related]
20. Tumor induced osteomalacia from a peripheral mesenchymal tumour of the foot.
Strydom A; Greeff W; Ferrao PNF; Saragas NP
Foot (Edinb); 2023 May; 55():101979. PubMed ID: 36871520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
